<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03614494</url>
  </required_header>
  <id_info>
    <org_study_id>UW18-003</org_study_id>
    <nct_id>NCT03614494</nct_id>
  </id_info>
  <brief_title>Piroxicam and Levonorgestrel Co-treatment for Emergency Contraception</brief_title>
  <official_title>Piroxicam and Levonorgestrel Co-treatment for Emergency Contraception: Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Hang Wun Raymond Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Family Planning Association of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomised controlled trial aimed at comparing the efficacy of levonorgestrel (LNG)
      co-administered with piroxicam or placebo for oral emergency contraception (EC). Piroxicam is
      a non-steroidal anti-inflammatory drug (NSAID) commonly used as a pain-killer in inflammatory
      conditions. Efficacy will be measured as the percentage of pregnancies prevented.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: To compare the percentage of pregnancies prevented by LNG co-administered with
      piroxicam or placebo for oral emergency contraception (EC) by a randomised controlled trial.

      Hypothesis to be tested: LNG plus piroxicam has higher percentage of pregnancies prevented
      compared with LNG plus placebo for oral emergency contraception.

      Design and subjects: This will be a prospective, randomised placebo-controlled clinical
      trial. Women attending the Family Planning Association of Hong Kong for oral EC within 72
      hours of unprotected sexual intercourse will be recruited.

      Study instruments: Prospective follow-up of subjects in the clinic for the primary and
      secondary outcomes.

      Interventions: Eligible subjects will be randomised to receive one of the two treatment
      regimens, i.e. Group A: a single dose of LNG 1.5 mg and piroxicam 40 mg, or Group B: a single
      dose of LNG 1.5mg and placebo under direct supervision.

      Main outcome measures: Percentage of pregnancies prevented (PPP) is the primary outcome
      measure. Secondary outcome measures include failure rate, rate of occurrence of side effects
      and pattern of the menstruation following EC.

      Data analysis:The percentage of pregnancies prevented, failure rate and rate of occurrence of
      side effects will be compared between groups using Fisher-Exact test. Continuous variables
      regarding menstrual pattern between the two groups will be compared by Mann-Whitney U test.

      Expected results: LNG plus piroxicam has a higher PPP compared to LNG plus placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2018</start_date>
  <completion_date type="Anticipated">October 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of pregnancies prevented</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pregnancy rate</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Significant adverse events</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">860</enrollment>
  <condition>Emergency Contraception</condition>
  <arm_group>
    <arm_group_label>Piroxicam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Piroxicam 40 mg (in 2 tablets) + levonorgestrel 1.5 mg single oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (2 tablets) + levonorgestrel 1.5 mg single oral dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Piroxicam 40 mg</intervention_name>
    <description>Additional co-treatment</description>
    <arm_group_label>Piroxicam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levonorgestrel 1.5mg</intervention_name>
    <description>Standard treatment</description>
    <arm_group_label>Piroxicam</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy women aged 18 years or above;

          -  requesting emergency contraception within 72 h of a single act of unprotected
             intercourse in the current menstrual cycle;

          -  having menstrual cycles between 24 and 42 days

          -  willing to abstain from further acts of unprotected intercourse and;

          -  available for follow-up over the next 6 weeks.

        Exclusion Criteria:

          -  post-abortion or postpartum and period have not yet returned,

          -  being on prescription drugs currently

          -  having unprotected intercourse in this cycle more than 72 hours or more than once
             before attending the clinic,

          -  being found pregnant at the time of presentation,

          -  breastfeeding,

          -  having been sterilized (or partner having been sterilized) or having intrauterine
             contraceptive device in-situ,

          -  uncertain about the date of the last menstrual period,

          -  having used hormonal contraceptive (including EC pill) or NSAID in the current or past
             one cycle,

          -  having history of asthma, urticarial or other allergic reactions to piroxicam, aspirin
             or other NSAIDs,

          -  having history of ischaemic heart disease in the past one year

          -  having history of pelvic ulcer disease and/or gastrointestinal bleeding
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Only females are eligible</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hang Wun Raymond Li, MBBS, FRCOG</last_name>
    <phone>+852 22554517</phone>
    <email>raymondli@hku.hk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ernest Hung Yu Ng, MD, FRCOG</last_name>
    <phone>+852 22554700</phone>
    <email>nghye@hku.hk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Family Planning Association of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sue Lo, MD, FRCOG</last_name>
      <phone>29197726</phone>
      <email>stlo@famplan.org.hk</email>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>July 29, 2018</study_first_submitted>
  <study_first_submitted_qc>July 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2018</study_first_posted>
  <last_update_submitted>October 9, 2018</last_update_submitted>
  <last_update_submitted_qc>October 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Dr. Hang Wun Raymond Li</investigator_full_name>
    <investigator_title>Clinical Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Piroxicam</keyword>
  <keyword>Levonorgestrel</keyword>
  <keyword>Placebo</keyword>
  <keyword>Randomised controlled control</keyword>
  <keyword>Emergency contraception</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Piroxicam</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

